Tackling TAMs for Cancer Immunotherapy: It's Nano Time.
Yishun Yang,Jianfeng Guo,Leaf Huang
DOI: https://doi.org/10.1016/j.tips.2020.08.003
IF: 17.638
2020-01-01
Trends in Pharmacological Sciences
Abstract:Tumor-associated macrophages (TAMs) are promising targets in oncology owing to their roles in the tumor microenvironment (TME) as promoters of tumor progression and inhibitors of antitumor immunity. Although therapeutic agents that eliminate TAMs, inhibit TAM recruitment, and/or normalize TAM polarization demonstrate great potential for clinical application, their efficacy remains limited. A major barrier to clinical translation is the paucity of efficient and safe methods to deliver TAM-targeting agents into tumors following systemic administration. Recent advances in nanotechnology and biomedical engineering provide opportunities for the development of nano targeted drug delivery systems (Nano-TDDS) in the treatment of cancer, and this strategy aims to overcome in vivo delivery barriers associated with TAM-targeting agents. The tumor microenvironment (TME) is a highly complex environment that surrounds tumors. Interactions between cancer cells/non-cancerous cells and cells/non-cell components in the TME support tumor initiation, development, and metastasis. Of the cell types in the TME, tumor-associated macrophages (TAMs) have gained attention owing to their crucial roles in supporting tumors and conferring therapy resistance. Recent developments in nanotechnology raise opportunities for the application of nano targeted drug-delivery systems (Nano-TDDS) in cancer therapy. We focus our discussion on current knowledge of TAMs, and describe recent examples of Nano-TDDS-based TAM modulation, highlighting strategies to overcome in vivo delivery barriers associated with the TME and their potential for clinical translation. The tumor microenvironment (TME) is a highly complex environment that surrounds tumors. Interactions between cancer cells/non-cancerous cells and cells/non-cell components in the TME support tumor initiation, development, and metastasis. Of the cell types in the TME, tumor-associated macrophages (TAMs) have gained attention owing to their crucial roles in supporting tumors and conferring therapy resistance. Recent developments in nanotechnology raise opportunities for the application of nano targeted drug-delivery systems (Nano-TDDS) in cancer therapy. We focus our discussion on current knowledge of TAMs, and describe recent examples of Nano-TDDS-based TAM modulation, highlighting strategies to overcome in vivo delivery barriers associated with the TME and their potential for clinical translation. the development of new blood vessels from a pre-existing vascular network. programmed cell death protein 1 (PD-1) is a cell-surface receptor expressed on activated T cells. PD-L1, which is overexpressed on tumor cells, binds to PD-1 on activated T cells, suppressing T cell-mediated tumor killing. PD-1/PD-L1 inhibitors (anti-PD-1/PD-L1) are immune checkpoint inhibitors targeting PD-1 or PD-L1. They are used to block the PD-1/PD-L1 pathway to treat human cancers. immune cells that play significant roles in host defense against infection by viruses and other pathogens by directly killing the infected cells. In tumors, CTLs release cytotoxic mediators such as IFN-γ, granzymes, and/or perforin to destroy cancer cells. ECs form the linings of the blood vessels and control the flow of substances/fluid into and out of a tissue. increased accumulation of macromolecules, such as liposomes, macromolecular drugs, and nanoparticles in tumors much more than in normal tissues. a cellular process whereby cells lose the epithelial features (e.g., cell polarity and cell–cell adhesion) and obtain mesenchymal characteristics (e.g., migration and invasion). It is a 'one-way' process that takes place through different cellular states. The EMT is related to tumor initiation/invasion/metastasis and drug resistance. a 3D network of extracellular components (e.g., collagens, enzymes, and glycoproteins) that can structurally and physiologically support neighboring cells. the predominant cell type of connective tissue. Fibroblasts regulate ECM turnover by the production of ECM components (e.g., type I, III, and IV collagens, and fibronectin) and ECM-degrading proteases (e.g., matrix metalloproteinases, MMPs). They also maintain the homeostasis of neighboring epithelial cells by the production of growth factors (e.g., VEGF). During wound repair, they produce ECM to create a scaffold for other effector cells, and generate cytoskeletal components for the contraction of wounds. the process by which cancer cells can avoid the immune system by disturbing any of the key T cell activities (e.g., T cell generation, T cell infiltration, and cell killing) that are indispensable to initiate and exert an anticancer immune response. generally comprise a water core enwrapped by lipid bilayer(s). In this amphiphilic structure, the core may encapsulate the water-soluble (hydrophilic) drugs, and water-insoluble (hydrophobic) drugs may be entrapped in the lipid bilayer(s). Cationic liposomes that are formed using lipids with positively charged groups may also bind nucleic acids via electrostatic interaction. the nature of monocytes and granulocytes (mostly neutrophils) is deformed under cancerous conditions, demonstrating immature phenotype and morphology, ineffective phagocytic activity, and high expression of anti-inflammatory cytokines. As a consequence, these aberrant cells proliferate and convert to MDSCs. There are two main subpopulations namely monocytic (M) and polymorphonuclear (PMN) MDSCs. M-MDSCs are phenotypically and morphologically similar to monocytes and may differentiate into M2 macrophages in tumors. orthotopic tumor models involve seeding tumor cells into the relevant organ of animal models. cells that enwrap ECs. They interact externally with the wall of capillaries, and promote the survival of ECs, but limit their proliferation at quiescent vessels. They also stabilize EC junctions to limit vascular permeability under normal conditions. immune cells that regulate the proliferation and activation of T and B cells for the maintenance of peripheral tolerance (the second branch of immunological tolerance after central tolerance, preventing autoimmune disease). In tumors, these cells inhibit anticancer immune responses. double-stranded noncoding RNAs 19–25 bp in length that play a key role in the RNA interference pathway. transmembrane receptors that play a crucial role in activating innate immunity by recognizing pathogen-associated molecular patterns. TLRs have been recognized as key factors involved in tumor pathogenesis, and regulate both tumor cells and tumor-infiltrating immune cells.